Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$97.3m

Atara Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ATRA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Sep 26BuyUS$999,994Brian CherryIndividual104,166US$9.60
17 Aug 26SellUS$40,883Anhco NguyenIndividual5,062US$8.08
18 May 26SellUS$22,036Yanina Grant-HuertaIndividual2,414US$9.13
18 May 26SellUS$47,845Anhco NguyenIndividual5,241US$9.13
07 May 26BuyUS$4,744,255EcoR1 Capital, LLCCompany507,407US$9.35
07 May 26SellUS$3,165,021Panacea Venture Management Co., Ltd.Company313,446US$10.10
07 May 26SellUS$3,165,021Panacea Venture Management Co., Ltd.Company313,446US$10.10
02 Mar 26SellUS$15,237Anhco NguyenIndividual2,996US$5.09
02 Mar 26SellUS$10,691Yanina Grant-HuertaIndividual2,104US$5.08
12 Jan 26SellUS$489,019Panacea Venture Management Co., Ltd.Company80,554US$6.07
17 Nov 25SellUS$23,788Yanina Grant-HuertaIndividual1,804US$13.19
17 Nov 25SellUS$38,437Anhco NguyenIndividual2,915US$13.19

Insider Trading Volume

Insider Buying: ATRA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ATRA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders369,2003.68%
VC/PE Firms1,318,89413.1%
Institutions2,179,50621.7%
General Public2,443,54024.3%
Hedge Funds3,726,57037.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 42.9%.

Top Shareholders

Top 25 shareholders own 74.37% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.5%
EcoR1 Capital, LLC
1,552,000US$15.0m1,460%0.73%
13.1%
Panacea Venture Management Co., Ltd.
1,318,894US$12.8m-19.2%9.42%
12.1%
Adiumentum Capital Management
1,209,395US$11.7m0%no data
8.47%
Adage Capital Management, L.P.
850,000US$8.2m21.4%0.01%
6.85%
Point72 Asset Management, L.P.
687,718US$6.7m254%0.01%
6.34%
Redmile Group, LLC
636,852US$6.2m44.2%0.38%
2.89%
Vanguard Capital Management, LLC
290,083US$2.8m15.4%no data
2.32%
Mackenzie Financial Corporation
233,249US$2.3m-25.6%no data
1.42%
Brian Cherry
142,486US$1.4m272%no data
0.84%
BlackRock, Inc.
84,455US$818.4k6.88%no data
0.75%
Geode Capital Management, LLC
75,128US$728.0k13.6%no data
0.5%
Staley Capital Advisers, Inc.
50,000US$484.5k0%0.02%
0.42%
Anhco Nguyen
41,950US$406.5k26.7%no data
0.39%
Acadian Asset Management LLC
38,845US$376.4k-70.3%no data
0.38%
Pascal Touchon
38,392US$372.0k0%no data
0.3%
Jane Street Group, LLC
30,345US$294.0k-10.4%no data
0.26%
State Street Investment Management
26,453US$256.3k0%no data
0.25%
Carol Gallagher
25,184US$244.0k0%no data
0.22%
Canada Life Investment Management Ltd.
22,194US$215.1k0%no data
0.22%
William Heiden
22,188US$215.0k54.5%no data
0.21%
Yanina Grant-Huerta
20,980US$203.3k23.4%no data
0.18%
Matthew Fust
18,188US$176.2k75.6%no data
0.18%
Eric Hyllengren
17,617US$170.7k0%no data
0.17%
Northern Trust Global Investments
16,591US$160.8k34.5%no data
0.16%
FMR LLC
16,238US$157.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 01:34
End of Day Share Price 2026/09/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Michael KingCitizens JMP Securities, LLC